Bone Biologics (BBLG) Total Non-Current Liabilities (2022 - 2026)
Bone Biologics (BBLG) posted quarterly Total Non-Current Liabilities of $417884.0 for Q4 2025, up 12.02% year-over-year from $373042.0 in Q4 2024, and up 25.46% quarter-over-quarter from $333081.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Total Non-Current Liabilities for 4 consecutive years, with $417884.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 12.02% year-over-year to $417884.0; the TTM figure through Dec 2025 stood at $417884.0 (up 12.02% YoY), while the FY2025 annual figure was $417884.0, up 12.02% from the prior year.
- Total Non-Current Liabilities rose to $417884.0 in Q4 2025 per BBLG's latest filing, from $333081.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.3 million in Q1 2023 and bottomed at $146186.0 in Q1 2024.
- Historically, Total Non-Current Liabilities has averaged $706885.5 across 4 years, with a median of $403729.0 in 2025.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 93.59% — and 2025, when it jumped 69.54%.
- Bone Biologics' Total Non-Current Liabilities stood at $888461.0 in 2022, then decreased by 12.7% to $775651.0 in 2023, then slumped by 51.91% to $373042.0 in 2024, then climbed by 12.02% to $417884.0 in 2025.
- Business Quant data shows BBLG's Total Non-Current Liabilities at $417884.0 in Q4 2025, $333081.0 in Q3 2025, and $403729.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 511,472.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 511,472.00 |
| Dec 31, 2025 | 417,884.00 |
| Sep 30, 2025 | 333,081.00 |
| Jun 30, 2025 | 403,729.00 |
| Mar 31, 2025 | 247,843.00 |
| Dec 31, 2024 | 373,042.00 |
| Sep 30, 2024 | 255,773.00 |
| Jun 30, 2024 | 276,852.00 |
| Mar 31, 2024 | 146,186.00 |
| Dec 31, 2023 | 775,651.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 2.28 Mn |
| Dec 31, 2022 | 888,461.00 |